2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
July 5th, 2025
Version: 1
School of Medical Science, National University of La Plata (UNLP)
cancer biology
biorxiv

Cannabidiol (CBD) as a novel inhibitor of HLA-G expression in human choriocarcinoma cell line (JEG-3)

Martinez, K. I.Open in Google Scholar•Palma, M. B.Open in Google Scholar•Sepulveda, F. J.Open in Google Scholar•Moavro, D. E.Open in Google Scholar•Carosella, E. D.Open in Google Scholar•Garcia, M. N.Open in Google Scholar•Riccillo, F. L.Open in Google Scholar

Cannabinoids have emerged as promising agents in cancer research due to their antitumor properties. While their effects on tumor growth and survival have been widely investigated, their impact on immune checkpoint regulation remains largely unexplored. In this study, we examined the effects of cannabidiol (CBD) and a high-CBD extract (CBD-HCE) on the expression of HLA-G in human choriocarcinoma JEG-3 cells. HLA-G is a non-classical HLA class I molecule associated with immune escape in tumors. Both CBD and CBD-HCE were found to reduce cell proliferation and migration, increase apoptosis, and significantly downregulate HLA-G expression at both the mRNA and protein levels. This inhibitory effect was observed to be both dose- and time-dependent, and it was completely reversible after the treatment was removed, indicating a dynamic and CBD-dependent modulation. These results provide the first experimental evidence of HLA-G downregulation by CBD and CBD-HCE, highlighting a novel immunomodulatory mechanism with potential therapeutic implications. By simultaneously targeting tumor cell viability and immune evasion, CBD-based compounds may enhance antitumor immune responses and improve the efficacy of immunotherapies. Further research involving additional tumor cell lines, in vivo models, and immune-relevant systems are necessary to validate and expand upon these findings.

Similar Papers

biorxiv
Sat Jul 05 2025
The PTPN1 and PTPN2 phosphatases are Cooperative Regulators of Cancer Cell Immune Evasion
Immune evasion by cancer cells remains a major barrier to the success of immune checkpoint blockade (ICB). Here, we identify the phosphatases PTPN1 and PTPN2 as cooperative regulators of tumor immune resistance. Dual genetic ablation of PTPN1/2 in cancer cells enhances Type I and II interferon signaling, MHCI and CXCL9 expression, and sensitizes tumor cells to cytotoxic T lymphocyte mediated killi...
Poirier, A.
•
Walback, E.
•
Su, R.
•
Aubry, I.
...•
Tremblay, M. L.
biorxiv
Sat Jul 05 2025
Cell Settling, Migration, and Stochastic Cancer Expression Suggest Potassium Flux Per H+- Sensitive KCN Members Associated with Oncogenes and Histone/DNA Modulators Potentially Initiates pH-Reversal
Attraction of glioblastoma cells to potassium was suspected when cells clustered around dying cells and they migrated towards serum (high [K+]) and a positive potassium gradient. Potassium channel proteins (KCN family, 90 members) mediating altered transmembrane flux may provide K+ that releases H+ bound to inner membranes in cancer cells for cytosolic proton transfer (possibly Grotthuss) to extru...
Beckner, M.
biorxiv
Sat Jul 05 2025
Labile iron pool dynamics do not drive ferroptosis potentiation in colorectal cancer cells
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the United States. CRC tumors exhibit aberrant iron accumulation, which supports tumor cell proliferation through multiple metabolic pathways. However, the oncogenic benefits of elevated iron must be counterbalanced by its potential to catalyze oxidative damage via reactive oxygen species generated from labile, redo...
Ponnusamy, V.
•
Randall, D. R.
•
Lee, Z.
•
Das, N. K.
...•
Hsu, P. P.
biorxiv
Fri Jul 04 2025
Multi-omic analysis of colorectal adenocarcinoma identifies a new subtype of myofibroblastic cancer-associated fibroblast expressing high level of B7-H3 and with poor prognosis value.
The high mortality rate of colorectal cancer (CRC) combined with the lack of non-toxic and efficient personalized treatments makes it urgent to develop new targeted therapies for this disease. B7-H3 appears to be a good target as it is overexpressed in tumor tissue compared to normal tissue. However, B7-H3 is a molecule with ambivalent functions and is expressed by different cell types. This compl...
Picard, M.
•
Guille, A.
•
Finetti, P.
•
De Rauglaudre, B.
...•
Mamessier, E.
biorxiv
Fri Jul 04 2025
Punctuated mutagenesis promotes multi-stepevolutionary adaptation in human cancers
The rate of acquisition of genomic changes in cancer has been the topic of much discussion, with several recent investigations finding evidence of punctuated evolution instead of gradual accumulation of such changes. Despite forays into the description and quantification of these punctuated events, the effects of such events on subsequent cancer evolution remain incompletely understood. Here we in...
Michor, F.
•
Graser, C. J.
•
Wu, W.
•
Christini, C.
•
Peljak, M.
biorxiv
Fri Jul 04 2025
An organotypic in vitro model of human papillomavirus-associated precancerous lesions allowing automated cell quantification for preclinical drug testing
Oncogenic human papillomaviruses (HPV) are causally responsible for invasive cancers and precancerous lesions. These lesions represent a considerable disease burden worldwide, yet no causally effective treatments are available. The development of HPV tumor models realistically reflecting the in vivo treatment situation is necessary for finding new effective and tissue-sparing treatments. This stud...
Köhler, R. M.
•
Stark, H.-J.
•
Martin, I.
•
Altmann, J.
...•
Prigge, E.-S.
biorxiv
Fri Jul 04 2025
DIFFERENTIAL ROLES OF RAD18 IN REPRESSING CARCINOGEN- AND ONCOGENE-DRIVEN MUTAGENESIS IN VIVO
The DNA repair protein RAD18 activates Y-family Trans-Lesion Synthesis (TLS) DNA polymerases that are DNA damage-tolerant and potentially error-prone. RAD18 is also frequently overexpressed and pathologically activated in cancer cells. However, the extent to which RAD18 shapes cancer genomes and impacts tumorigenesis is unclear. Therefore, we tested the effect of Rad18 status on chemically-induced...
Anand, J.
•
Brown, B. W.
•
Lou, J.
•
Gu, Q.
...•
Vaziri, C.
biorxiv
Fri Jul 04 2025
Bioelectric and Epigenetic Landscapes in Lateralized Breast Tumors Reveal Distinct Tumor Microenvironment Signatures.
Cell communication within the tumor microenvironment (TME) plays a pivotal role in cancer progression, yet little is known about whether this communication differs between anatomically paired organs. Here, we report that breast tumors arising in the left (L) versus right (R) mammary glands exhibit significant asymmetry in composition, bioelectric state, and epigenetic regulation suggesting the exi...
Real, S.
•
Laurito, S.
•
Gonzalez, P.
•
Bello, O.
...•
Moreno, M. R.
biorxiv
Fri Jul 04 2025
The IFN I response in tumor cells is shaped by PARP7-p300/CBP interactions through distinct loss- and gain-of-function mechanisms
PARP7, a mono-ADP-ribosyl (MAR) transferase, is a key suppressor of the type I interferon (IFN-I) IFNb in various tumor cells and a validated drug target. This negative regulation is reversed by small-molecule inhibitors of PARP7 catalytic activity, resulting in increased IFNb expression. Yet, the mechanism of action of PARP7 inhibitors remains unclear because the relevant substrates of PARP7-medi...
Siordia, I. R.
•
Rieth, S.
•
Jeltema, D.
•
Morgan, R.
...•
Cohen, M. S.